Assessment of the Drug Susceptibility of Plasmodium falciparum Clinical Isolates from Africa by Using a Plasmodium Lactate Dehydrogenase Immunodetection Assay and an Inhibitory Maximum Effect Model for Precise Measurement of the 50-Percent Inhibitory Concentration
Open Access
- 1 October 2006
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (10) , 3343-3349
- https://doi.org/10.1128/aac.00367-06
Abstract
The extension of drug resistance among malaria-causing Plasmodium falciparum parasites in Africa necessitates implementation of new combined therapeutic strategies. Drug susceptibility phenotyping requires precise measurements. Until recently, schizont maturation and isotopic in vitro assays were the only methods available, but their use was limited by technical constraints. This explains the revived interest in the development of replacement methods, such as the Plasmodium lactate dehydrogenase (pLDH) immunodetection assay. We evaluated a commercially controlled pLDH enzyme-linked immunosorbent assay (ELISA; the ELISA-Malaria antigen test; DiaMed AG, Cressier s/Morat, Switzerland) to assess drug susceptibility in a standard in vitro assay using fairly basic laboratory equipment to study the in vitro resistance of malaria parasites to major antimalarials. Five Plasmodium falciparum clones and 121 clinical African isolates collected during 2003 and 2004 were studied by the pLDH ELISA and the [8-(3)H]hypoxanthine isotopic assay as a reference with four antimalarials. Nonlinear regression with a maximum effect model was used to estimate the 50% inhibitory concentration (IC(50)) and its confidence intervals. The two methods were observed to have similar reproducibilities, but the pLDH ELISA demonstrated a higher sensitivity. The high correlation (r = 0.98) and the high phenotypic agreement (kappa = 0.88) between the two methods allowed comparison by determination of the IC(50)s. Recently collected Plasmodium falciparum African isolates were tested by pLDH ELISA and showed drug resistance or decreased susceptibilities of 62% to chloroquine and 11.5% to the active metabolite of amodiaquine. No decreased susceptibility to lumefantrine or the active metabolite of artemisinin was detected. The availability of this simple and highly sensitive pLDH immunodetection assay will provide an easier method for drug susceptibility testing of malaria parasites.Keywords
This publication has 24 references indexed in Scilit:
- Simple Histidine-Rich Protein 2 Double-Site Sandwich Enzyme-Linked Immunosorbent Assay for Use in Malaria Drug Sensitivity TestingAntimicrobial Agents and Chemotherapy, 2005
- Simple and Inexpensive Fluorescence-Based Technique for High-Throughput Antimalarial Drug ScreeningAntimicrobial Agents and Chemotherapy, 2004
- Comparative Structural Analysis and Kinetic Properties of Lactate Dehydrogenases from the Four Species of Human Malarial ParasitesBiochemistry, 2004
- Field Evaluation of a Novel Colorimetric Method—Double-Site Enzyme-Linked Lactate Dehydrogenase Immunodetection Assay—To Determine Drug Susceptibilities of Plasmodium falciparum Clinical Isolates from Northwestern ThailandAntimicrobial Agents and Chemotherapy, 2004
- Histidine-Rich Protein II: a Novel Approach to Malaria Drug Sensitivity TestingAntimicrobial Agents and Chemotherapy, 2002
- Hypoxanthine: a low molecular weight factor essential for growth of erythrocyticPlasmodium falciparumin a serum-free mediumParasitology, 1996
- Plasmodium falciparum and Plasmodium vivax: Lactate-Dehydrogenase Activity and Its Application for in Vitro Drug Susceptibility AssayExperimental Parasitology, 1995
- Plasmodium falciparum: In Vitro Studies of the Pharmacodynamic Properties of Drugs Used for the Treatment of Severe MalariaExperimental Parasitology, 1993
- Plasmodium falciparum: Assessment of in vitro growth by [3H]hypoxanthine incorporationExperimental Parasitology, 1983
- Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution techniqueAntimicrobial Agents and Chemotherapy, 1979